Zéna Wimana

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

Géraldine Gebhart, Laetitia E. Lamberts, Zéna Wimana et al. · Annals of Oncology · 2015 · 348 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Paget bone disease demonstrated on 68Ga-PSMA ligand PET/CT

Carlos Artigas, J. Alexiou, Camilo Garcia et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2015 · 95 citations

Medicine, Nuclear Medicine, Oncology +14

Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors

Jana Jeschke, Évelyne Collignon, Clémence Al Wardi et al. · Nature Cancer · 2021 · 78 citations · Full text

Medicine, Molecular Biology, Oncology +14

A dosimetry procedure for organs-at-risk in 177Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours

Gwennaëlle Marin, Bruno Vanderlinden, Ioannis Karfis et al. · Physica Medica · 2018 · 65 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Prediction of¹⁷⁷Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study

Magdalena Mileva, Gwennaëlle Marin, Hugo Levillain et al. · Journal of Nuclear Medicine · 2023 · 49 citations · Full text

Medicine, Nuclear Medicine, Oncology +17